PMID- 31094396
OWN - NLM
STAT- MEDLINE
DCOM- 20191210
LR  - 20191217
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 10
IP  - 6
DP  - 2019 Jun 19
TI  - Hypoglycemic effects of wheat bran alkyresorcinols in high-fat/high-sucrose diet 
      and low-dose streptozotocin-induced type 2 diabetic male mice and protection of 
      pancreatic beta cells.
PG  - 3282-3290
LID - 10.1039/c8fo02396d [doi]
AB  - In the present study, the hypoglycemic effects of wheat bran alkyresorcinols 
      (ARs) were investigated in type 2 diabetes mellitus (T2DM) mice induced by a 
      high-fat/high-sucrose diet (HFSD) combined with low dose streptozotocin (STZ). 
      After the consumption of 5 mg kg-1 d-1 acarbose (positive control) and different 
      doses of wheat bran ARs (50, 200 and 500 mg kg-1 d-1) for 4 weeks, the fasting 
      blood glucose (FBG) levels in T2DM mice were found to be reduced significantly (p 
      < 0.05), and the effects of 200 and 500 mg kg-1 d-1 administration were better 
      than that of 50 mg kg-1 d-1. The results of the oral glucose tolerance test 
      (OGTT) also showed that both acarbose and AR administration significantly 
      increased the glucose tolerance of the T2DM mice. Then, the fasting serum insulin 
      levels (FINS) were significantly reduced by AR treatment, and the effect of 500 
      mg kg-1 d-1 AR administration was better than that of 5 mg kg-1 d-1 acarbose. The 
      profile of plasma lipids was analyzed simultaneously, and the results showed that 
      the contents of total cholesterol (TC), triglyceride (TG), and low-density 
      lipoprotein cholesterol (LDL-C) were significantly decreased, while the content 
      of high-density lipoprotein cholesterol (HDL-C) was increased significantly after 
      200 and 500 mg kg-1 d-1 AR treatment (p < 0.05). Furthermore, 200 and 500 mg kg-1 
      d-1 ARs significantly increased the content of hepatic glycogen and the activity 
      of glucokinase (p < 0.01) in T2DM mice. The relative mRNA levels of glucose 
      transporter 2 (GLUT2) in the liver tissue were increased markedly in 200 and 500 
      mg kg-1 d-1 AR treatment groups (p < 0.01), and the relative mRNA levels of 
      glucose transporter 4 (GLUT4) in the epididymal adipose tissue were increased 
      significantly in all AR treatment groups, especially significantly higher than 
      acarbose (p < 0.01). Histological analyses revealed that treatment with ARs 
      exerted a protective role on pancreatic beta-cells. The results indicated that ARs 
      could be an effective hypoglycemic active ingredient in whole grain diets.
FAU - Tu, Jie
AU  - Tu J
AD  - College of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 
      212018, China. tujie@just.edu.cn.
FAU - Liu, Guanhui
AU  - Liu G
FAU - Cao, Xitao
AU  - Cao X
FAU - Zhu, Shuyun
AU  - Zhu S
FAU - Li, Qiang
AU  - Li Q
FAU - Ji, Gengsheng
AU  - Ji G
FAU - Han, Yanhui
AU  - Han Y
FAU - Xiao, Hang
AU  - Xiao H
LA  - eng
PT  - Journal Article
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
RN  - 0 (Blood Glucose)
RN  - 0 (Dietary Fiber)
RN  - 0 (Glucose Transporter Type 2)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Resorcinols)
RN  - 0 (Triglycerides)
RN  - 57-50-1 (Sucrose)
RN  - 5W494URQ81 (Streptozocin)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - YUL4LO94HK (resorcinol)
SB  - IM
MH  - Animals
MH  - Blood Glucose/metabolism
MH  - Cholesterol/blood
MH  - Diabetes Mellitus, Type 2/*drug therapy/etiology/genetics/metabolism
MH  - Diet, High-Fat/*adverse effects
MH  - Dietary Fiber/*administration & dosage
MH  - Glucose Tolerance Test
MH  - Glucose Transporter Type 2/genetics/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/chemistry
MH  - Insulin/blood
MH  - Insulin-Secreting Cells/*drug effects/metabolism
MH  - Liver/drug effects/metabolism
MH  - Male
MH  - Mice
MH  - Resorcinols/*administration & dosage/chemistry
MH  - Streptozocin/adverse effects
MH  - Sucrose/*adverse effects
MH  - Triglycerides/blood
EDAT- 2019/05/17 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/05/17 06:00
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/05/17 06:00 [entrez]
AID - 10.1039/c8fo02396d [doi]
PST - ppublish
SO  - Food Funct. 2019 Jun 19;10(6):3282-3290. doi: 10.1039/c8fo02396d.